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Abstract
Agaricus bisporus, Cantharellus cibarius, Imleria badia, and Lentinula edodes are among the most popular species of 
edible mushrooms in Poland. These edible mushrooms are an important source of biologically active substances exhibiting 
beneficial (e.g., antioxidant, antitumor, antimicrobial, anti-inflammatory) effects on the human body. The fruiting bodies of 
edible mushrooms are also a valuable source of lovastatin, which belongs to a group of compounds, called statins, commonly 
used as cholesterol-lowering drugs. Due to the presence of lovastatin, edible mushrooms can be useful in the prevention of 
hypercholesterolemia. Therefore, the aim of this study was to determine the content of lovastatin in the selected species of 
edible mushrooms and to evaluate its release into artificial digestive juices. This study was the first to determine the release 
of lovastatin into digestive juices after the extraction of materials obtained from edible mushrooms. The largest amount 
of lovastatin was found in the fruiting bodies of C. cibarius (67.89 mg/100 g d.w.), and the smallest in those of L. edodes 
(0.95 mg/100 g d.w.). The amount of lovastatin released from the extracts of the examined species into digestive juices was 
found to be relatively low. The highest content after incubation in artificial gastric juice was detected for the fruiting bodies 
of L. edodes (0.02 mg/100 g d.w.) and after incubation in the intestinal juice for the mycelium from the in vitro cultures of 
L. edodes (0.51 mg/100 g d.w.). Thus, the results of the present study showed that due to its ability to accumulate lovastatin 
from culture medium, L. edodes mycelium can be used to obtain a product with increased hypolipidemic activity.
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Introduction
The interest in edible mushrooms has been constantly 
growing since the last decade due to their prohealth and 
therapeutic activities which are proved in many scientific 
experiments. Edible mushrooms are a source of valu-
able biologically active substances, including phenolic and 
indolic compounds, carotenoids, flavonoids, sesquiterpe-
noids, glucans, glycoproteins, triterpenoids, sterols, toco-
pherols, antibiotics, vitamins, and bioelements, which are 
present in them in significant quantities and often act syn-
ergistically. It has been proven that these substances exert 
immunostimulatory, anticancer, antibacterial, antifungal, 
anti-inflammatory, and antioxidant effects [1–7]. In addi-
tion to these therapeutic compounds, mushrooms contain 
numerous dietary components and exogenous amino acids. 
Moreover, the protein derived from the fruiting bodies of 
mushrooms is well assimilable. The high nutritional value 
of mushrooms is also associated with their presence of vita-
mins, minerals, unsaturated fatty acids, and dietary fiber 
[8–11]. Furthermore, the fruiting bodies of edible mush-
rooms are a valuable source of lovastatin which belongs 
to a group of compounds called statins, commonly used as 
cholesterol-lowering drugs [12–16]. Lovastatin is a naturally 
occurring compound that selectively blocks the synthesis of 
endogenous cholesterol. It was first isolated from Aspergil-
lus terreus in 1978 and introduced into the medical field by 
Merck in 1987 [17].
Lovastatin consists of a six-part lactone ring with a 
hydroxyl group and a partially hydrogenated naphthalene 
with a hydroxyl substituent esterified with a 2-methylbutyric 
acid residue (Fig. 1).
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Lovastatin is present in the living organisms in the form 
of lactone which is insoluble in water, while its active form 
β-hydroxy acid is water soluble. Thus, lovastatin is a pre-
cursor, which during enzymatic reactions is transformed 
from the form of lactone to hydroxy acid that competitively 
blocks 3-hydroxy 3-methyl-glutaryl-coenzyme A (HMG-
CoA) reductase. As a result, the transformation of HMG-
CoA to mevalonate, which is a key stage in the synthesis of 
cholesterol, is blocked. This mechanism leads to a reduction 
in cholesterol synthesis, and hence its concentration in the 
liver, and increases the expression of the low-density lipo-
protein receptor on the hepatocyte cell membrane, which is 
captured from the blood, and decreases its plasma level [17, 
18]. Medicines from the statins group also show pleiotropic 
effects, which include protection of the vascular endothe-
lium and stimulation of its regeneration, stabilization of 
the atherosclerotic plaque, influence on the clotting system, 
and involvement in anti-inflammatory and antioxidation pro-
cesses [19]. It has now been stated that the pathophysiology 
of atherosclerosis is associated with the induction of inflam-
matory processes in the vascular wall and, therefore, statins 
play an important role in the prevention and treatment of 
this disease.
It has been shown that lovastatin can exert a multidi-
rectional effect in various diseases such as osteoporosis, 
neurodegenerative diseases, rheumatoid arthritis, ischemic 
heart disease, and nonalcoholic fatty liver disease [20–24]. 
Lovastatin also exhibits promising anticancer properties 
by suppressing the genes involved in cell division, increas-
ing the activity of cell cycle inhibitors and decreasing the 
activity of cyclins B and D1, activating caspase-3, and 
inhibiting antiapoptotic factors [25–27]. Lovastatin helps 
to prevent metastasis and, therefore, it is administered 
together with anticancer drugs and during radio- and 
chemotherapies. For instance, this compound can be used 
in the treatment of malignant mesothelioma since it plays 
a role in the prevention of cancer proliferation and angio-
genesis by inhibiting the activation of vascular endothelial 
growth factor-2 (VEGFR-2). Thus, lovastatin, in combi-
nation with a VEGFR-2 inhibitor, can exhibit a stronger 
inhibitory effect on tumor growth [28]. In addition, the 
antifungal effect of lovastatin has been demonstrated by 
the growth inhibition of Rhodotorula rubra, Mucor rac-
emosus, and Candida albicans [29].
Due to the presence of dietary substances, edible mush-
rooms are classified as functional foods [9, 11]. Due to 
this advantage, it is possible to enrich the mycelium from 
in vitro cultures with appropriate precursors of active 
substances to obtain an increased amount of those sub-
stances. Various crop modifications are also applied; for 
example, in the case of Agaricus bisporus species, expos-
ing the developing fruiting bodies to UV light leads to 
a high content of vitamin  D3 [30]. Similarly, lovastatin 
content can be increased in the fruiting bodies of edible 
mushrooms by modifying the medium composition and 
optimizing the culture conditions. Mushrooms also have 
the ability to accumulate drugs and, hence, there is a pos-
sibility to maximize the content of desired drugs in their 
fruiting bodies [31–33].
The aim of this study was to determine the content of 
lovastatin in the lyophilized fruiting bodies of four edi-
ble mushroom species, namely A. bisporus, Cantharel-
lus cibarius, Imleria badia, and Lentinula edodes, and 
in the lyophilized mycelium from the in vitro cultures of 
these species. Qualitative and quantitative analyses were 
performed using reversed-phase high-performance liquid 
chromatography (RP-HPLC). To determine the actual 
amount of lovastatin available to the human body, the 
release of this compound from mushroom material (fruit-
ing bodies and mycelium from in vitro cultures) into arti-
ficial digestive juices was evaluated in a Gastroel-2014 
apparatus. Thus far, there are no studies available evalu-
ating the release of lovastatin from fruiting bodies and 
mycelium from the in vitro cultures of edible mushrooms 
into digestive juices. The present study is the first to deter-
mine the content of lovastatin in digestive juices after 
extraction of the fruiting bodies of edible mushrooms and 
mycelium from in vitro cultures. This process worked most 
efficiently for L. edodes and, therefore, this species was 
selected for further research, in which the ability of the 
in vitro cultures of this species to accumulate lovastatin 
from the culture medium was evaluated. For this purpose, 
the medium was enriched with lovastatin and tablets of 
two commercial preparations containing this compound—
Liprox and Lovasterol. The results showed that bioaccu-
mulation of lovastatin by mycelium may allow enriching 
the mushroom culture to obtain a product with increased 
anticholesterol activity. In the next stage of the study, the 
release of lovastatin from the lyophilized biomass of the 
in vitro cultures of L. edodes into artificial digestive juices 
was evaluated.
 
Fig. 1  Structural formula of lovastatin




The fruiting bodies of A. bisporus (J.E. Lange) Imbach, 
L. edodes (Berk.) Pegler of commercial origin, and C. 
cibarius Fr. and I. badia (Fr.) Vizzini collected from the 
natural environment—mixed forests of Southern Poland 
near Nowy Sącz—were used in the experiment. They were 
cleaned of plants and remnants and then lyophilized. The 
taxonomic identification was performed with MycoKey 
4.1 software (http://www.mycok ey.com) by an expert 
B. Muszyńska. Representative voucher specimens were 
deposited at the Department of Pharmaceutical Botany, 
Jagiellonian University Medical College, Krakow, Poland.
Mycelial cultures
To carry out the experiment, in vitro cultures of the above-
mentioned species were established on a modified liquid 
medium according to Oddoux [34].
The mycelial cultures were derived from the previously 
prepared explants of the fruiting bodies of A. bisporus and 
L. edodes of commercial origin as well as from C. cibarius 
and I. badia collected from the natural environment. For 
this purpose, a part of the hymenium was first defatted 
with 70% ethanol for several seconds, and the material 
was sterilized with a 15% solution of sodium chlorate for 
2 min. Then the fragments of fruiting bodies were rinsed 
several times with redistilled water and transferred to the 
Oddoux solid medium (laminar airflow). After 2 weeks of 
in vitro culture, 250 mL of the modified liquid medium 
(Oddoux) was transferred to the solid medium.
In the next stage of the experiment, mycelium from the 
in vitro cultures of L. edodes was transferred to 250 mL of 
the modified liquid medium containing 20 mg of lovasta-
tin in the form of a chemical compound (Sigma-Aldrich, 
Darmstadt, Germany), weighed on the analytical scales, 
and in the form of tablets of Liprox and Lovasterol prepa-
rations containing 20 mg of lovastatin, respectively.
Experimental cultures
The cultures were established on the liquid medium to 
obtain the highest possible amount of biomass for use in 
further analyses. The cultures were shaken at 140 rpm 
(Altel, Łódź) and then incubated at a temperature of 
25 ± 2 °C under a cycle resembling natural light condi-
tions. Liquid in vitro cultures were shaken for 2 weeks, 
and then again transferred to a new medium to obtain a 
sufficient amount of biomass for the study.
After 2 weeks of establishing the in vitro culture of the 
tested mushroom species on the liquid medium, biomass 
was separated from the medium and rinsed several times 
with four-time distilled water. The obtained biomass was 
frozen and then lyophilized. The lyophilized samples were 
weighed.
Preparation of artificial digestive juices
A solution of artificial saliva with a pH of 6.7 (4.355 g 
 K2HPO4, 3.407 g  Na2HPO4, 15.018 g  KHCO3, 5.844 g 
NaCl, 0.142 g  MgCl2, 80.114 g citric acid, 1.665 g  CaCl2) 
[35] was prepared by dissolving the weighed contents in a 
small amount of four-time distilled water. Then the solution 
was transferred to a flask and topped up with water up to 
1000 mL.
A solution of artificial gastric juice with a pH of 2 (2.0 g 
NaCl and 3.2 g pepsin) [36] was prepared by dissolving the 
weighed contents in a small amount of four-time distilled 
water. The solution was transferred to a flask, and then 
80 mL of 1 M HCl was added. The solution was topped up 
with water up to 1000 mL.
A solution of artificial intestinal juice with a pH of 8.0 
(0.020 g pancreatic extract, 0.125 g bile salts, and 8.4 g 
 NaHCO3) [37] was prepared by dissolving the weighed con-
tents in four-time distilled water and made up to 1000 mL 
with water.
Digestion of lyophilized samples of fruiting bodies 
and biomass from in vitro cultures in artificial 
digestive juices
An amount of 2.0 g of lyophilized fruiting bodies of A. 
bisporus, C. cibarius, I. badia, and L. edodes and their 
biomass was weighed. The contents were crushed and then 
transferred to flasks containing 3 mL of artificial saliva solu-
tion. The samples were incubated in this solution for 1 min 
(approximate physiological time of food residence in the 
oral cavity).
Then 20 mL of artificial gastric juice was added to each 
flask. The samples were extracted in this solution at 37 °C 
for 60 min in a Gastroel-2014 apparatus. The solutions were 
filtered through a tissue filter, and 20 mL of artificial intesti-
nal juice was added to the biomass obtained. The solutions 
were incubated under similar conditions for 150 min, and 
were filtered through tissue filters and then through mem-
brane filters (Millex, Millipore Corporation, USA). The 
amount of lovastatin in the obtained filtrates was determined 
using the RP-HPLC method.
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Digestion of L. edodes mycelium 
on lovastatin‑enriched media in artificial digestive 
juices
To carry out an experiment on media enriched with lovas-
tatin, lyophilized biomass from in vitro cultures (enriched 
with lovastatin, Liprox, or Lovasterol) and the control sam-
ple were ground separately in a mortar. Then 2.0 g of the test 
portions was weighed and transferred to flasks. The contents 
of each flask were moistened with 3 mL of artificial saliva 
and left for 1 min. Then the contents were decanted and 
20 mL of gastric juice was added to each flask. In the next 
step, they were placed in the Gastroel-2014 apparatus, and 
the thermostat was set at 37 °C. Each sample was digested 
in the gastric juice for 60 min. After an appropriate period of 
time, the contents of the flasks were filtered through pleated 
filter papers. The filtrate was left to determine lovastatin, and 
the digested materials together with the filter papers were 
placed in the flasks. Afterward, 20 mL of artificial intestinal 
juice was added for further digestion. The flasks contain-
ing the prepared samples were placed in the Gastroel-2014 
device for 150 min each.
Preparation of methanol extracts
An amount of 2.0 g of lyophilized fruiting bodies of A. 
bisporus, C. cibarius, I. badia, and L. edodes and biomass 
from the in vitro cultures of these species was weighed. The 
contents were transferred to beakers containing 100 mL of 
methanol each. The samples were extracted using ultrasound 
(Polsonic Sonic 3, frequency 40 kHz) for 20 min, and then 
the solutions were filtered into crystallizers. The obtained 
filtrate was evaporated and used for qualitative and quantita-
tive determinations of lovastatin content using the RP-HPLC 
method.
Determination of lovastatin content in mushroom 
material using the RP‑HPLC method
Chromatographic separation was performed using a high-
performance liquid chromatography (HPLC) analyzer 
(Merck Hitachi). The process was carried out in an isocratic 
system with a mobile phase of constant composition. The 
apparatus was equipped with a UV detector (λ = 238 nm), a 
column (Purospher RP18 14 × 200 mm, 5 µm), and a lamp 
(L7100). During each measurement, 20 µL of the analyzed 
sample was injected, and the measurement was performed 
within 15 min. All measurements were carried out using 
a previously prepared developing system [acetonitrile and 
0.1% phosphoric acid in the ratio of 60:40 (v/v)]. The reten-
tion time of the standard substance was 12.75 min.
Extracts obtained after the digestion of fruiting bod-
ies and mycelium from the in vitro cultures of the tested 
mushroom species in artificial digestive juices were placed 
in crystallizers for evaporation. The dry residue was then 
dissolved in 1.5 mL of methanol and transferred to Eppen-
dorf tubes using membrane filters (Millex, Millipore Corpo-
ration, USA). Extracts obtained after extraction using ultra-
sound and after evaporation were also dissolved in methanol, 
purified with membrane filters, and then analyzed.
The identification of the lovastatin was made by com-
paring the retention times of sample peaks with the stand-
ard compound. To confirm the presence of lovastatin in 
the tested extracts, the standard solutions of lovastatin was 
added as internal standards. The presence of the tested 
compound in the sample showed up as an increase in peak 
height for the appropriate retention time. The quantitative 
analysis of lovastatin was carried out using the calibration 
curve method. The chromatogram of lovastatin standard is 
presented in Fig. 2.
Statistical analysis
Statistical analyses were conducted using Microsoft Excel 
2010 and the commercially available package GraphPad 
Prism v3.02 (GraphPad Software, San Diego, CA). The lov-
astatin concentrations in in vitro cultures of L. edodes were 
evaluated using one-way ANOVA test with Tukey’s post hoc 
multiple comparisons. A p value < 0.05 was accepted as sta-
tistically significant. Data were presented as the mean ± SD 
from three independent experiments (n = 3).
Results and discussion
Determination of lovastatin content in the tested 
fruiting bodies and in vitro cultures
The least squares linear regression was employed to statisti-
cally evaluate the changes in peak areas vs concentration of 
lovastatin. The calibration was made by the analysis of five 
standard solutions containing different concentrations of lov-
astatin in the range 0.0625–1 mg/mL. The linear regression 
equation was y = 68756616x + 636261. The determination 
coefficient (R2) obtained for the linear model was found to 
be 0.9997. The LOD and LOQ values were 0.0144 mg/mL 
and 0.0435 mg/mL, respectively.
The analysis of the obtained methanol extracts con-
firmed the presence of lovastatin in the tested species of 
edible mushrooms. The use of HPLC allowed determining 
the amount of lovastatin in the methanol extracts, which 
were obtained from the fruiting bodies of A. bisporus, C. 
cibarius, I. badia, and L. edodes as well as from the in vitro 
mycelial cultures of these species, and artificial digestive 
juices. After ultrasound extraction, lovastatin was deter-
mined both qualitatively and quantitatively in all the edible 
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mushroom species investigated. The results of the analy-
ses were expressed as the amount of lovastatin contained 
in 100 g of dry matter of each of the examined species. 
The amount of lovastatin in the methanol extracts obtained 
from the fruiting bodies of the studied species was esti-
mated as follows: A. bisporus—30.79 mg/100 g d.w., L. 
edodes—0.95 mg/100 g d.w., C. cibarius—67.89 mg/100 g 
d.w., and I. badia—6.21  mg/100  g d.w. Similarly, the 
amount of lovastatin in the methanol extracts obtained from 
the in vitro mycelial cultures of the studied species was esti-
mated as follows: A. bisporus—47.96 mg/100 g d.w., C. 
cibarius—17.58 mg/100 g d.w., I. badia—16.57 mg/100 g 
d.w., and L. edodes—3.48 mg/100 g d.w. (Fig. 3).
The highest content of lovastatin was found in the fruiting 
bodies of C. cibarius species (67.89 mg/100 g d.w.) and the 
lowest in the fruiting bodies of L. edodes (0.95 mg/100 g 
d.w.). An exemplary chromatogram for the determination of 
lovastatin in the methanol extract obtained from the fruiting 
bodies of C. cibarius is shown in Fig. 4.
A study by Chen showed that the fruiting bodies of 
many edible mushrooms contain significant amounts of 
lovastatin: A. bisporus—56.54 mg/100 g d.w., Boletus 
Fig. 2  Chromatogram of lovastatin standard
Fig. 3  Lovastatin content 
(mg/100 g d.w.) in the lyophi-
lized biomass of the mushroom 
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edulis—32.73  mg/100  g d.w., and Pleurotus ostrea-
tus—60.65 mg/100 g d.w [38]. The study also showed 
the amount of lovastatin in the fruiting bodies of edible 
mushrooms collected from different countries: Japan—
16.53 mg/100 g d.w., Korea—21.64 mg/100 g d.w., and 
Taiwan– 21.64 mg/100 g d.w. [38]. Lin et al. determined 
the amount of lovastatin in the fruiting bodies of L. 
edodes as 0.27 mg/100 g d.w.[30]. To date, P. ostreatus 
is most studied for lovastatin content because it is one 
of the edible mushroom species containing a significant 
amount of this compound. P. ostreatus exerts a hypocho-
lesterolemic effect and was found to inhibit lipid peroxi-
dation in rats and rabbits. It was demonstrated that a diet 
containing 10% of the dried fruiting bodies of P. ostreatus 
reduces the occurrence and size of atherosclerotic plaques 
[39]. To our knowledge, no study has determined the lov-
astatin content in the extracts from the fruiting bodies of 
C. cibarius and I. badia.
In the present study, a higher content of lovastatin was 
found in the extracts from in vitro mycelial cultures com-
pared to the extracts from the fruiting bodies of mush-
room species collected from the natural environment, 
except C. cibarius.
In another experiment, the content of lovastatin was 
determined in two types of in vitro cultures of P. ostreatus 
species (solid-state fermentation—0.33 mg/mL, in-depth 
fermentation—0.74 mg/mL) and their powdered fruiting 
bodies (0.47 mg/mL) [13]. Lin et al. determined the con-
tent of lovastatin in mycelium from the in vitro cultures 
of this species to be 2.22 mg/100 g d.w.[30].
Determination of lovastatin content after digestion 
of the test material in artificial digestive juice 
solutions
The analysis of the obtained methanol extracts confirmed the 
presence of lovastatin in the tested mushroom species after 
extraction into artificial digestive juices. The results of the 
analysis were expressed as the amount of lovastatin released 
from 100 g of dry matter of each of the tested species. Both 
artificial gastric juice, after 60-min incubation preceded by 
incubation of the material in artificial saliva, and artificial 
intestinal juice, after 150-min incubation of the tested mate-
rial preceded by incubation in artificial saliva and artificial 
gastric juice, were tested. An example of a chromatogram of 
lovastatin extracted from artificial digestive juices is shown 
in Fig. 5.
After incubation of the examined material in artificial 
gastric juice, lovastatin was determined qualitatively and 
quantitatively only for L. edodes (0.02 mg/100 g d.w.). In 
the samples of the other species, the content of lovastatin 
was less than 0.01 mg/100 g d.w.
The release of lovastatin into artificial intestinal juice 
after 150 min of incubation (after a previous incubation 
in artificial saliva solution and artificial gastric juice) was 
confirmed in the samples of all the tested species of edible 
mushrooms, except the A. bisporus mycelium obtained from 
in vitro cultures; however, in most samples, the amount of 
lovastatin was below 0.01 mg/100 g d.w. The highest con-
tent of lovastatin was found in the extract from the in vitro 
cultures of L. edodes (0.51 mg/100 g d.w.). Figure 6 shows 
Fig. 4  Chromatogram obtained by analyzing a sample from the fruiting bodies of C. cibarius 
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the percentage of lovastatin determined in artificial intestinal 
juice in relation to the total content determined in the metha-
nol extract of the mushroom materials studied. Because the 
in vitro cultures of L. edodes were found to have the highest 
content, this species was selected for further study.
Evaluation of L. edodes ability to accumulate 
lovastatin
The experiment showed that mycelium from the in vitro 
cultures of L. edodes established on a modified Oddoux 
medium enriched with lovastatin yielded a higher biomass 
than the control sample cultured without the addition of 
lovastatin. Biomass gains were as follows: 3.22 g/250 mL 
medium for L. edodes + lovastatin, 1.65 g/250 mL medium 
for L. edodes + Liprox, 1.62 g/250 mL medium for L. 
edodes + Lovasterol, and 0.83 g/250 mL medium for L. 
edodes (control sample). Although the highest amount of 
biomass was obtained from the in vitro cultures enriched 
with lovastatin, enrichment with commercial preparations 
also resulted in a significantly higher amount of biomass 
compared to the control sample. From the biotechnologi-
cal point of view, this means that it is possible to obtain 
in vitro cultures of L. edodes with an increased hypocho-
lesterolemic activity.
The analysis of the results showed that lovastatin is pre-
sent in each of the studied species of edible mushrooms, 
but it is released into artificial digestive juices only in very 
small amounts. The highest content after incubation in 
artificial gastric juice was detected in the fruiting bodies 
of L. edodes (0.02 mg/100 g d.w.) and after incubation in 
the intestinal juice in mycelium from the in vitro cultures 
of L. edodes (0.51 mg/100 g d.w.).
Fig. 5  Example of a chromato-
gram obtained by the analysis of 
L. edodes extract from in vitro 
cultures on modified Oddoux 
medium after 60-min incuba-
tion in gastric juice and then 
150-min incubation in intestinal 
juice
Fig. 6  Percentage of lovastatin 
determined in artificial intesti-
nal juice in relation to its total 
content in the methanol extract 
of the mushroom materials 
tested
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To evaluate the ability of L. edodes mycelium to accumu-
late lovastatin, the content of this substance was determined 
in the mycelium from the in vitro cultures of this species 
established on Oddoux medium enriched with 20 mg of 
lovastatin per 250 mL of medium or one tablet of Liprox 
or Lovasterol (20 mg of lovastatin) per 250 mL of medium. 
It was demonstrated that the in vitro cultures of L. edodes 
are capable of accumulating lovastatin. Its content in myce-
lium from the lovastatin-enriched medium was significantly 
higher compared to the control sample. The in vitro cultures 
on nonenriched medium contained 3.48 mg of lovastatin per 
100 g of dry matter, while those grown on enriched medium 
contained up to 100 times more lovastatin per 100 g of dry 
matter. Thus, significant differences (p < 0.05) were found 
in the content of lovastatin between the control L. edodes 
mycelium and the mycelium grown on Oddoux medium 
enriched with this substance or with one tablet of Liprox 
or Lovasterol. The most effective bioaccumulation of lov-
astatin was observed in the in vitro cultures enriched with 
pure substance compared to the two commercial prepara-
tions (Fig. 7).
Examination of lovastatin release from mycelium 
from the in vitro cultures of L. edodes into artificial 
digestive juices
It was shown that lovastatin from biomass obtained 
from the in vitro cultures of L. edodes on medium not 
enriched with the tested substance did not release into 
artificial digestive juices. Both in gastric and intestinal 
juice, lovastatin was found in amounts not exceeding the 
limit of quantification. In the case of in vitro cultures of L. 
edodes established on modified Oddoux medium enriched 
with lovastatin (both preparations and pure compound), 
lovastatin was found in intestinal juice after digestion of 
the tested material for 30 min in gastric juice. The results 
showed no clear correlation between the amount of lov-
astatin accumulated in the mycelium from in vitro cul-
tures and the amount of lovastatin released into artificial 
digestive juices (Fig. 8). Studies on the bioavailability of 
biologically active substances from mushroom material 
are scarce. Several reports on the release of bioelements 
and other organic compounds from food including mush-
rooms into artificial digestive juices were published, but 
study of bioavailability of lovastatin from mushroom is 
a new research direction [40–43]. It is well known that 
lovastatin is present in edible mushrooms from the Basidi-
omycota taxon, and their regular consumption can lead to 
lowering cholesterol levels and thus preventing from car-
diovascular diseases [43, 44]. There are, however, reports 
on the bioavailability of lovastatin present in red yeast 
rice products [45]. It was proved that this natural mate-
rial may contain lovastatin with a higher dissolution rate 
and reduced crystallinity compared to commercially avail-
able formulations, making it more bioavailable [45]. In 
addition, previous experiments on the bioavailability of 
lovastatin have shown that it is a substance with low bio-
availability, which is why it is necessary to create forms 
of lovastatin that will allow the most effective absorption 
in the human body [45–47].
On the basis of the conducted analyses, it was found that 
the content of lovastatin was higher in the in vitro cultures 
than in the fruiting bodies of the tested mushrooms. This 
study proved the low availability of lovastatin after con-
sumption, despite its high content in methanol extracts of 
the abovementioned species. Therefore, to utilize the antia-
therosclerotic effect of mushrooms, alcoholic extracts are 
recommended.
Fig. 7  Lovastatin content in biomass extracts from the in vitro cultures of L. edodes (mg/100 g dry matter). The data are presented as a mean SD 
from three independent experiments (n = 3). For statistically significant results, P < 0.05
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Conclusion
In vitro cultures of L. edodes effectively accumulated lov-
astatin and, therefore, the in vitro culture media can be 
supplemented with this compound to obtain mycelium 
with high hypocholesterolemic activity. Additionally, 
enrichment of the medium with lovastatin increased the 
biomass gains in relation to the cultures not enriched with 
this compound. The amount of lovastatin accumulated 
in mycelium from the medium enriched with commer-
cial preparations was lower than that from the medium 
enriched with pure compound, but the ability to release the 
compound into artificial digestive juices differed between 
the cultures enriched with commercial preparations and 
pure substance.
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